Entreprise · 22/12/19941 min de lecture
National Institute of Child Health and Human Development; Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Use of Orally Active Derivatives of 1,3,5(10)-estratriene and Pharmaceutical Compositions Thereof
Traduction automatique locale · Langue originale de la source
Résumé
The National Institutes of Health is seeking licensees and/or CRADA partners for the further development, evaluation, and commercialization of novel esters of estradiol and pharmaceutical compositions thereof. The invention claimed in U.S. Patent Application Serial No. 08/122,853 entitled ``Orally Active Derivatives of 1,3,5(10)-estratriene'' (Kim, H.K., Blye, R.P., and Bialy, G.), filed August 17, 1993, is available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under a CRADA for clinical and research applications described below in Supplementary Information. To expedite the research, development, and commercialization of this new class of drugs, the National Institutes of Health is seeking one or more license agreements and/or CRADAs with pharmaceutical or biotechnology companies in accordance with the regulations governing the transfer of Government-developed agents. Any proposal to use or develop these drugs will be considered.